001     148366
005     20240229112702.0
024 7 _ |a 10.1136/esmoopen-2019-000583
|2 doi
024 7 _ |a pmid:31798980
|2 pmid
024 7 _ |a pmc:PMC6863673
|2 pmc
024 7 _ |a altmetric:70365069
|2 altmetric
037 _ _ |a DKFZ-2019-02922
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Mock, Andreas
|0 P:(DE-He78)8f7c3bc1451193551c2458d93222536a
|b 0
|e First author
245 _ _ |a Community-driven development of a modified progression-free survival ratio for precision oncology.
260 _ _ |a London
|c 2019
|b BMJ
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1681384178_19513
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecularly guided therapy (PFS2) divided by the PFS interval associated with the last prior systemic therapy (PFS1), above 1.3 or, in some studies, above 1.33 or 1.5.To investigate if the concept of PFS ratios is in agreement with actual response evaluations by physicians, we conducted a survey among members of the MASTER (Molecularly Aided Stratification for Tumor Eradication Research) Programme of the German Cancer Consortium who were asked to classify the success of molecularly guided therapies in 194 patients enrolled in the MOSCATO 01 trial based on PFS1 and PFS2 times.A comparison of classification profiles revealed three distinct clusters of PFS benefit assessments. Only 29% of assessments were consistent with a PFS ratio threshold of 1.3, whereas the remaining 71% of participants applied a different classification scheme that did not rely on the relation between PFS times alone, but also took into account absolute PFS1 intervals. Based on these community-driven insights, we developed a modified PFS ratio that incorporates the influence of absolute PFS1 intervals on the judgement of clinical benefit by physicians. Application of the modified PFS ratio to outcome data from two recent precision oncology trials, MOSCATO 01 and WINTHER, revealed significantly improved concordance with physician-perceived clinical benefit and identified comparable proportions of patients who benefited from molecularly guided therapies.The modified PFS ratio may represent a meaningful clinical endpoint that could aid in the design and interpretation of future precision oncology trials.
536 _ _ |a 314 - Tumor immunology (POF3-314)
|0 G:(DE-HGF)POF3-314
|c POF3-314
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Heilig, Christoph E
|0 P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6
|b 1
700 1 _ |a Kreutzfeldt, Simon
|0 P:(DE-He78)e5972dddc3c8d1412db29ba54fed83ba
|b 2
700 1 _ |a Huebschmann, Daniel
|0 P:(DE-He78)a5218e4871866cd5ab2312e594ca403d
|b 3
700 1 _ |a Heining, Christoph
|0 P:(DE-He78)1464357f7ec5faf677a390a414e50c88
|b 4
700 1 _ |a Schröck, Evelin
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Brors, Benedikt
|0 P:(DE-He78)fc949170377b58098e46141d95c72661
|b 6
700 1 _ |a Stenzinger, Albrecht
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Jäger, Dirk
|0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1
|b 8
700 1 _ |a Schlenk, Richard
|0 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
|b 9
700 1 _ |a Glimm, Hanno
|0 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9
|b 10
700 1 _ |a Fröhling, Stefan
|0 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
|b 11
|e Last author
700 1 _ |a Horak, Peter
|0 P:(DE-He78)5ea1944c122bc098a81df27a05572719
|b 12
|e Last author
700 1 _ |a Network, DKTK MASTER
|b 13
|e Collaboration Author
700 1 _ |a Apostolidis, Leonidas
|b 14
700 1 _ |a Augustin, Marinela
|b 15
700 1 _ |a Aust, Daniela
|b 16
700 1 _ |a Bhatti, Irfan Ahmed
|b 17
700 1 _ |a Bloehdorn, Johannes
|b 18
700 1 _ |a Brendel, Cornelia
|b 19
700 1 _ |a Britschgi, Christian
|b 20
700 1 _ |a Braess, Jan
|b 21
700 1 _ |a Burdach, Stefan
|b 22
700 1 _ |a Busch, Elena
|b 23
700 1 _ |a Casuscelli, Jozefina
|b 24
700 1 _ |a Desuki, Alexander
|b 25
700 1 _ |a Deutsch, Thomas
|b 26
700 1 _ |a Dietrich, Mareike
|b 27
700 1 _ |a Ehmer, Ursula
|b 28
700 1 _ |a Ettrich, Thomas J
|b 29
700 1 _ |a Falkenhorst, Johanna
|b 30
700 1 _ |a Fehm, Tanja
|b 31
700 1 _ |a Flörcken, Anne
|b 32
700 1 _ |a Forschner, Andrea
|b 33
700 1 _ |a Fuxius, Stefan
|b 34
700 1 _ |a Gonzales-Carmona, Maria
|b 35
700 1 _ |a Griesinger, Frank
|b 36
700 1 _ |a Grill, Sabine
|b 37
700 1 _ |a Gröschel, Stefan
|b 38
700 1 _ |a Haag, Georg Martin
|b 39
700 1 _ |a Haag, Ulrich
|b 40
700 1 _ |a Halama, Niels
|b 41
700 1 _ |a Hebart, Holger
|b 42
700 1 _ |a Heidger, Nina
|b 43
700 1 _ |a Hermes, Barbara
|b 44
700 1 _ |a Hess, Georg
|b 45
700 1 _ |a Hettmer, Simone
|b 46
700 1 _ |a Hoechstetter, Manuela
|b 47
700 1 _ |a Hoffmann, Martin
|b 48
700 1 _ |a Hüttner, Felix J
|b 49
700 1 _ |a Illert, Anna L
|b 50
700 1 _ |a Jenzer, Maximilian
|b 51
700 1 _ |a Kasper, Bernd
|b 52
700 1 _ |a Kasper-Virchow, Stefan
|b 53
700 1 _ |a Kindler, Thomas
|b 54
700 1 _ |a Koscielniak, Ewa
|b 55
700 1 _ |a Krönke, Jan
|b 56
700 1 _ |a Kühn, Michael
|b 57
700 1 _ |a Kunzmann, Volker
|b 58
700 1 _ |a Lang, Alois
|b 59
700 1 _ |a Leichsenring, Jonas
|b 60
700 1 _ |a Livingstone, Elisabeth
|b 61
700 1 _ |a Liotta, Lucia
|b 62
700 1 _ |a Luley, Kim
|b 63
700 1 _ |a Mack, Elisabeth
|b 64
700 1 _ |a Martens, Uwe M
|b 65
700 1 _ |a Metzeler, Klaus
|b 66
700 1 _ |a Middeke, Jan Moritz
|b 67
700 1 _ |a Möhrmann, Lino
|b 68
700 1 _ |a Jayarama-Naidu, Roopa
|b 69
700 1 _ |a Pape, Ulrich-Frank
|b 70
700 1 _ |a Perkhofer, Lukas
|b 71
700 1 _ |a Pfeufer, Arne
|b 72
700 1 _ |a Pixberg, Constantin
|b 73
700 1 _ |a Quante, Michael
|b 74
700 1 _ |a Rendenbach, Bernhard
|b 75
700 1 _ |a Rieke, Damian
|b 76
700 1 _ |a Rothermundt, Christian
|b 77
700 1 _ |a Sagerer, Andre Norbert
|b 78
700 1 _ |a Salzmann, Martin
|b 79
700 1 _ |a Saur, Dieter
|b 80
700 1 _ |a Schilling, Bastian
|b 81
700 1 _ |a Schleicher, Jan
|b 82
700 1 _ |a Schlenska-Lange, Anke
|b 83
700 1 _ |a Schmidt, Thomas
|b 84
700 1 _ |a Schmitz, Sophia
|b 85
700 1 _ |a Schölch, Sebastian
|b 86
700 1 _ |a Shah, Rajiv
|b 87
700 1 _ |a Shoumariyeh, Khalid
|b 88
700 1 _ |a Siebenhüner, Alexander
|b 89
700 1 _ |a Singh, Martin
|b 90
700 1 _ |a Siveke, Jens
|b 91
700 1 _ |a Springfeld, Christoph
|b 92
700 1 _ |a Starke, Helen
|b 93
700 1 _ |a Strobel, Sophia
|b 94
700 1 _ |a Teleanu, Veronica
|b 95
700 1 _ |a Thon, Niklas
|b 96
700 1 _ |a Wagner, Sebastian
|b 97
700 1 _ |a Walle, Thomas
|b 98
700 1 _ |a Westphalen, Benedikt
|b 99
700 1 _ |a Whitlock, Bettina
|b 100
700 1 _ |a Winkler, Eva
|b 101
700 1 _ |a Wirsik, Naita Maren
|b 102
700 1 _ |a Woydack, Lena
|b 103
700 1 _ |a Bois, Angelika Zabel-du
|b 104
700 1 _ |a Zschäbitz, Stefanie
|b 105
773 _ _ |a 10.1136/esmoopen-2019-000583
|g Vol. 4, no. 6, p. e000583 -
|0 PERI:(DE-600)2844985-X
|n 6
|p e000583
|t ESMO open
|v 4
|y 2019
|x 2059-7029
909 C O |p VDB
|o oai:inrepo02.dkfz.de:148366
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)8f7c3bc1451193551c2458d93222536a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)e5972dddc3c8d1412db29ba54fed83ba
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)a5218e4871866cd5ab2312e594ca403d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)1464357f7ec5faf677a390a414e50c88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)fc949170377b58098e46141d95c72661
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)5ea1944c122bc098a81df27a05572719
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-314
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Tumor immunology
|x 0
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
920 1 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
920 1 _ |0 I:(DE-He78)V960-20160331
|k V960
|l HI-Stem
|x 2
920 1 _ |0 I:(DE-He78)L301-20160331
|k L301
|l DKTK Dresden
|x 3
920 1 _ |0 I:(DE-He78)D120-20160331
|k D120
|l D120 Angewandte Tumor-Immunität
|x 4
920 1 _ |0 I:(DE-He78)B330-20160331
|k B330
|l Angewandte Bioinformatik
|x 5
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B340-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)V960-20160331
980 _ _ |a I:(DE-He78)L301-20160331
980 _ _ |a I:(DE-He78)D120-20160331
980 _ _ |a I:(DE-He78)B330-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21